PharmaFocus Today – Page 164 – media

FDA approves Eicos’s Aurlumyn for severe frostbite treatment

The US Food and Drug Administration (FDA) has approved Eicos Sciences’s Aurlumyn (iloprost) injection, a new treatment for adults with severe frostbite to lower the risk of amputation of fingers or toes. Aurlumyn contains iloprost, a vasodilator that opens blood vessels and stops blood clotting, as its active ingredient. The efficacy of iloprost in treating severe frostbite was established through an open-label controlled trial in 47 adult subjects. Participants were randomised into three groups, with group one receiving iloprost intravenously for six hours daily for up to eight days along with aspirin and standard of care. Groups two and three were administered other medications, with and without iloprost, which are not approved for frostbite treatment. The trial’s primary efficacy measure was bone scans on day seven following the frostbite incident to predict the need for amputation. The scans showed that none of the subjects who received iloprost alone (group one) ...
- Source: drugdu
- 127
- February 17, 2024
People with chest pain more likely to develop heart and circulatory diseases

Around one million adults in the UK visit their GP every year due to chest pain Researchers from Keele University have identified the key risk factors of people with unattributed chest pain developing heart and circulatory diseases. The study, published in the European Journal of Preventative Cardiology, was funded by the British Heart Foundation (BHF). Every year, around one million adults in the UK visit their GP due to chest pain and many will not receive a diagnosis, with only a few receiving preventative treatments. Previous research has shown that people living with unattributed chest pain have a higher risk of experiencing future heart health problems compared to those without. Researchers developed risk calculators to identify people at a high risk of developing future heart and circulatory diseases, and to pinpoint the key factors that influence that risk. The team used anonymised information from the health records of over 600,000 ...
- Source: drugdu
- 113
- February 17, 2024
Study suggests heart stress test could transform patient diagnosis

The EST identified 30% of patients with a blood supply/demand mismatch Researchers from King’s College London (KCL) have revealed that the revival of a heart stress test was successful when put to the test against contemporary standards in heart care. Published in the Journal of American College of Cardiology, the electrocardiogram exercise stress test (EST) was accurate in identifying abnormalities in the heart’s blood supply. Previously, the EST was a popular way of assessing patients with angina – attacks of chest pain caused by reduced blood flow to the heart. The test required a patient to exercise on a treadmill or stationary bike while a cardiologist distinguished whether the blood supply to the heart muscle matched the demand during physical stress. However, due to its perceived inaccuracies, the EST test fell out of favour. KCL researchers, however, questioned this after discovering that an abnormal EST was successful in picking up ...
- Source: drugdu
- 108
- February 17, 2024
CRISPR Test Diagnoses Mpox Faster Than Lab-Based PCR Method

Mpox, formerly known as monkeypox, is a rare viral disease transmitted through physical contact and typically presents mild symptoms like fever, rash, and swollen lymph nodes, though severe cases can require medical intervention. Due to its contagious nature, prompt testing is crucial for isolation and treatment purposes. Current mpox testing requires laboratory equipment and may take hours to yield results. Now, new research suggests a way for faster mpox testing that could be done in any clinic. Researchers at Pennsylvania State University (University Park, PA, USA) have utilized CRISPR, the groundbreaking gene-editing technology, to develop a faster mpox test. For their study, the team designed a genetic sequence with an attached reporter specifically targeting the mpox virus. The test employs programmable CRISPR RNA that binds to the target and a protein called Cas12a, which together cleaves the reporter to produce fragments of varying sizes. Using nanopore sensing technology, these reporter ...
- Source: drugdu
- 126
- February 16, 2024
Portable Rapid PCR Diagnostic to Detect Gonorrhea and Antibiotic Susceptibility

Gonorrhea, ranked as the second most reported bacterial sexually transmitted infection (STI), affected approximately 82 million people globally in 2020. The infection can lead to severe health complications, including pelvic inflammatory disease, chronic pelvic pain, and infertility. Untreated gonorrhea may progress to the bloodstream, posing a life-threatening risk and increasing the likelihood of HIV infection. Many cases go unreported due to asymptomatic patients, implying that the actual burden of the disease may be significantly higher. Now, a rapid test aims to identify gonorrhea and also determine its antibiotic susceptibility. Visby Medical (San Jose, CA, USA) has been awarded up to USD 1.8 million by CARB-X (Boston, MA, USA) for the development of a portable rapid polymerase chain reaction (PCR) diagnostic to identify the presence of Neisseria gonorrhoeae (NG), the pathogen responsible for gonorrhea, and ascertain its susceptibility to ciprofloxacin. Ciprofloxacin was once a primary oral antibiotic for treating NG but ...
- Source: drugdu
- 149
- February 16, 2024
US lawmakers urge administration to take action against Wuxi

In a letter to the US Departments of Treasury, Defense, and Commerce, four lawmakers have expressed their concerns regarding biotech WuXi AppTec and its subsidiary WuXi Biologics’ supposed ties to the Chinese military. The 12 February letter from Chairman Mike Gallagher (R-WI), Senator Bill Hagerty (R-TN), Ranking Member Raja Krishnamoorthi (D-IL), and Senator Gary Peters (D-MI) asked that the administration add Wuxi to US government control lists given the biotech’s alleged ties to the Chinese Communist Party (CCP) and involvement in the CCP genocide of Uyghurs in Xinjiang, Reuters first reported. In addition, the letter alleges that the biotech is “closely affiliated” with the People’s Liberation Army (PLA), claiming that the biotech’s chairman and CEO Dr. Li has “personally commended CCP branch work in the company and has called on Party branches and members to play an active role in the company.” Lawmakers also claim that CEO Chen Zhisheng of ...
- Source: drugdu
- 105
- February 16, 2024
Changing protocol language and site actions are key to making trials inclusive

Changing the language used in trial protocols and continually conversing with sites are some ways by which trialists can make clinical research more inclusive of the LGBTQIA+ community, say experts. On the fourth and final day of the 2024 Summit for Clinical Ops Executives (SCOPE) Summit held in Orlando, a panel discussed the most important changes that can make clinical trials more inclusive of the community. Shir Netanel, associate director of patient advocacy and clinical trial advocacy for Janssen, spoke about her experience with the company launching a transgender-inclusive Phase III trial for prostate cancer. Netanel mentioned how changing the language to be gender neutral, for example, allowed the protocol and eligibility criteria to include any patients who are affected with prostate cancer, regardless of their gender. Additionally, Janssen has also created and deployed a toolkit at trial sites to help investigators be more inclusive, she added. Michel Reid, head ...
- Source: drugdu
- 96
- February 16, 2024
Millions of people to view digital prescriptions via the NHS app

Prescriptions ordered via the app are expected to save around 1.85 million hours in 2024 NHS England has announced that its new digital prescription service has been added to the NHS App. The launch of the service follows a successful trial last year that involved over a million users. In alignment with the NHS campaign to encourage more people to use the app, the digital prescription service will allow millions of patients to see when their prescriptions have been issued and will allow them to view their prescribed medication. Patients who are waiting for an elective hospital treatment will also be able to see the average waiting time for their procedure at their local trust. Users without a nominated pharmacy will be given a barcode via the app to collect their prescription from any pharmacy, as opposed to using a paper version. Anyone with a nominated pharmacy will continue to ...
- Source: drugdu
- 110
- February 16, 2024
NHS launches BRCA testing programme for people of Jewish descent

Individuals with Jewish ancestry are six times more likely to carry a genetic fault The NHS has announced the launch of a new BRCA gene testing programme to identify cancer risk early in individuals with Jewish ancestry. People with Jewish ancestry are about six times more likely to carry a genetic fault, which can increase the risk of developing some cancers, than the general population. Across the next two years, the national NHS Jewish BRCA Testing Programme plans to identify thousands more people carrying faults in the BRCA genes so they can seek early access to surveillance and prevention services. In alignment with the health services drive to catch tumours earlier, when they are easier to treat, anyone over the age of 18 years with Jewish ancestry will be eligible to receive a simple genetic saliva test to look for the presence of BRCA1 or BRCA2 faults. BRCA1 and BRCA2 ...
- Source: drugdu
- 135
- February 16, 2024
New Stool Test for Detecting Colorectal Cancer Could Reduce Unnecessary Colonoscopies

Globally, around 1.9 million people are diagnosed with colorectal cancer each year, resulting in approximately 935,000 deaths. Early detection is key, as colorectal cancer can be cured if found early. However, symptoms like weight loss or blood in the stool often emerge too late for effective intervention. Consequently, many countries have initiated population-based screening programs. These programs commonly utilize the fecal immunochemical test (FIT), which detects the blood protein hemoglobin in stool samples. Colorectal cancer screening programs have been effective in diagnosing the disease at earlier stages and reducing mortality rates. Despite the current test’s effectiveness, there is a need for improvement, particularly in detecting larger premalignant polyps before they become invasive. Early detection would allow for these polyps to be removed during a colonoscopy instead of requiring surgery. Researchers at the Netherlands Cancer Institute (Amsterdam, the Netherlandsl) have been developing a new test, the multitargetFIT-test (mtFIT), which measures hemoglobin ...
- Source: https://www.labmedica.com/molecular-diagnostics/articles/294800242/new-stool-test-for-detecting-colorectal-cancer-could-reduce-unnecessary-colonoscopies.html
- 187
- February 15, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.